Breast Cancer

The DONNA Foundation will host its signature fall event, the DONNA 5K at TPC Sawgrass.

I share my journey facing breast cancer at 39, learning my numbers, trusting my doctor, and becoming my own advocate for informed treatment choices.

Jennie Smythe continues the conversation following her initial discussion on early detection self-advocacy during Breast Cancer Awareness Month.

Young women with breast cancer experience significant declines in body image, sexual satisfaction, and sexual interest both during and after treatment.

As a survivor, I see pink ribbons everywhere, but what we really need is more research, better treatments, and real change for those living with cancer.

It’s October, and social media sites are full of vendors selling merchandise featuring pink ribbons. But here's the thing...

In locally recurrent inoperable or metastatic TNBC, Datroway resulted in improvement in overall survival and progression-free survival.

October is Breast Cancer Awareness Month, and CURE is here to address some of the most common questions patients have after a breast cancer diagnosis.

As we kick off Breast Cancer Awareness Month, it’s an opportune time to reflect on some of the most important breast cancer stories shared last month.

A breast cancer survivor reflects whimsically on how she might have aged with two breasts instead of one.

The FDA approved Guardant360 CDx to identify adults with ESR1-mutated, ER-positive, HER2-negative breast cancer eligible for treatment with Inluriyo.

Jennie Smythe, a breast cancer survivor, shared her journey from diagnosis to survivorship in an interview with CURE during Breast Cancer Awareness Month.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Penn Medicine researchers found two oral drugs eliminated dormant breast cancer cells in most patients, with relapse rates dropping to about 4% after seven years.

Napo Pharmaceuticals applied for orphan drug designation for Mytesi to treat diarrhea in patients with breast cancer and brain metastases on targeted therapy.

Enhertu significantly improved invasive disease-free survival when compared with Kadcyla in high-risk HER2-positive early breast cancer.

I faced breast cancer and unexpected body changes with resilience and humor, learning to adapt and find strength in the process.

As a metastatic breast cancer patient, I want to control what I can, including my diet and exercise.

The FDA granted priority review to an sBLA for first-line treatment with Enhertu plus Perjeta in unresectable or metastatic HER2-positive breast cancer.

I’ve lived 22 years beyond my breast cancer diagnosis, and each day I honor survival with gratitude, wellness, and hope for myself and others.

Going through breast cancer has pushed me to do things I never thought I would.

CURE spoke with Amanda Davis at the John Theurer Cancer Center in Hackensack, New Jersey.

CURE spoke with nurse and breast cancer survivor Amanda Davis at the John Theurer Cancer Center.

Giredestrant plus Afinitor improved survival without progression in ER-positive advanced breast cancer.

Many of the choices I've made regarding yard maintenance relate to my hopes to mitigate the risk of more cancer.